Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer

Table 4 Summary of the molecules of action, inhibitory concentration values, and mechanisms of action of existing anticancer drugs for N6-methyladenosine-targeted therapy

Drug	Role in cancer	Cancer type	Target	IC50	Mechanism	Ref.
STM2457	Tumour inhibitor	AML	METTL3	16.9 nM	m6A↓/HOXA1018↓/MYC19↓	[142]
UZH1a	Tumour inhibitor	AML	METTL3	4.6 μM	Inhibits METTL3 catalytic activity and decreases m6A level and mRNA transcription level	[143]
CS1	Tumour inhibitor	AML	FTO		m6A↑/LILRB4↓/MYC↓/CEBPA↓/RARA↑/ASB2↑	[145]
FB23	Tumour inhibitor	AML	FTO	0.8-1.5 μM	m6A↑/MYC↓/CEBPA↓/RARA↑/ASB2↑	[148]
MA	Tumour inhibitor	AML	FTO	17.4 μM	Binds to FTO and inhibits demethylation	[147]
R-2HG	Tumour inhibitor	AML	FTO		m6A↑/FTO↓/MYC↓CEBPA↓	[146]
Rhein	Tumour inhibitor	Liver cancer	FTO/ALKBH5	30 mM	Competitive binding of FTO to substrate binding sites and increased m6A levels	[149]
2-[(1-hydroxy-2-oxo-2-phenylethyl) sulfanyl] acetic acid	Tumour inhibitor	AML	ALKBH5	0.84 μM	Binds ALKBH5 and decreases m6A levels	[150]
4-{[(furan-2-yl) methyl]amino}-1,2-diazinane-3,6-dione	Tumour inhibitor	AML	ALKBH5	1.79 μM	Binds ALKBH5 and decreases m6A levels	[150]

M6A: N6-methyladenosine; IC50: Inhibitory concentration.